tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Keratosis, Actinic D055623 3 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Retrognathia D063173 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Scorpion Stings D065008 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Prescott TA et al. A yeast chemical genetics approach identifies the compound 3,4,5-trimethoxybenzyl isothiocyanate as a calcineurin inhibitor. 2014 FEBS Lett. pmid:24374339
Perlman RL and Rao PS Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment. 2014 Drugs Aging pmid:24399579
Tanaka K et al. Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases. 2014 J. Hum. Genet. pmid:24352002
Kim EJ et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 2014 Am. J. Transplant. pmid:24354871
Huang K et al. Novel role for NFAT3 in ERK-mediated regulation of CXCR4. 2014 PLoS ONE pmid:25514788
Saito K et al. Severe diffuse duodenitis successfully treated with intravenous tacrolimus after colectomy for ulcerative colitis. 2014 Intern. Med. pmid:25366006
Siddiqui A et al. Chemometric methods for the quantification of crystalline tacrolimus in solid dispersion by powder X-ray diffractrometry. 2014 J Pharm Sci pmid:24585357
Labrador J et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. 2014 Bone Marrow Transplant. pmid:24566710
Singh K et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 2014 Am. J. Transplant. pmid:25359003
Balato A et al. Tacrolimus does not alter the production of several cytokines and antimicrobial peptide in Malassezia furfur-infected-keratinocytes. 2014 Mycoses pmid:24512536
Li CJ et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. 2014 PLoS ONE pmid:24465960
Silva-Cunha A et al. Evaluation of the pharmacokinetics and ocular tolerance of a microemulsion containing tacrolimus. 2014 J Ocul Pharmacol Ther pmid:24199740
Diémé B et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. 2014 Transplantation pmid:24598938
Grillo E et al. Necrobiosis lipoidica. 2014 Aust Fam Physician pmid:24600675
Kimura Y et al. Evaluation of the Multi-ImmunoTox Assay composed of 3 human cytokine reporter cells by examining immunological effects of drugs. 2014 Toxicol In Vitro pmid:24603311
Suarez-Kurtz G et al. Pharmacogenomic implications of population admixture: Brazil as a model case. 2014 Pharmacogenomics pmid:24444410
Shilbayeh S The impact of genetic polymorphisms on time required to attain the target tacrolimus levels and subsequent pharmacodynamic outcomes in pediatric kidney transplant patients. 2014 Saudi J Kidney Dis Transpl pmid:24625991
Kurzawski M et al. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. 2014 Pharmacogenomics pmid:24444408
Xue F et al. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients. 2014 Pediatr Transplant pmid:24438215
Wang XZ et al. Increased intracellular adenosine triphosphate level as an index to predict acute rejection in kidney transplant recipients. 2014 Transpl. Immunol. pmid:24211610
Lapeyraque AL et al. Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. 2014 Pediatr. Nephrol. pmid:24435759
Højfeldt JW et al. Bifunctional ligands allow deliberate extrinsic reprogramming of the glucocorticoid receptor. 2014 Mol. Endocrinol. pmid:24422633
Chen YK et al. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation. 2014 PLoS ONE pmid:25310192
Saso S et al. Uterine allotransplantation in a rabbit model using aorto-caval anastomosis: a long-term viability study. 2014 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:25306223
Mekaj AY et al. Application of topical pharmacological agents at the site of peripheral nerve injury and methods used for evaluating the success of the regenerative process. 2014 J Orthop Surg Res pmid:25303779
Meyer KC et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. 2014 Eur. Respir. J. pmid:25359357
Souto-Rodríguez R et al. Differences in the incidence and clinical evolution of early neurotoxicity after liver transplantation based on tacrolimus formulation used in the immunosuppressive induction protocol. 2014 Transplant. Proc. pmid:25420839
Zhu X et al. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults. 2014 Blood Cells Mol. Dis. pmid:24931461
Salehi-Najafabadi Z et al. The gamma-butyrolactone receptors BulR1 and BulR2 of Streptomyces tsukubaensis: tacrolimus (FK506) and butyrolactone synthetases production control. 2014 Appl. Microbiol. Biotechnol. pmid:24562179
Xue W et al. Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis. 2014 Chin. Med. J. pmid:24931259
Taguchi K et al. False tacrolimus concentrations measured by antibody-conjugated magnetic immunoassay in liver transplant patient: 2 case reports and literature review. 2014 Exp Clin Transplant pmid:24206050
Casey MJ et al. Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. 2014 Transplantation pmid:24717218
Trotter JF and Lizardo-Sanchez L Everolimus in liver transplantation. 2014 Curr Opin Organ Transplant pmid:25254569
Stifft F et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. 2014 Transplantation pmid:24686426
Funaro D et al. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. 2014 J. Am. Acad. Dermatol. pmid:24704090
Doligalski CT et al. Sublingual administration of tacrolimus: current trends and available evidence. 2014 Pharmacotherapy pmid:25251980
Demmers MW et al. Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. 2014 Transplantation pmid:24704664
Koren G and Rieder M Measuring oral bioavailability of tacrolimus. 2014 Pediatr Transplant pmid:25250966
Størset E et al. Importance of hematocrit for a tacrolimus target concentration strategy. 2014 Eur. J. Clin. Pharmacol. pmid:24071959
Ghanem RC et al. Tacrolimus for the treatment of subepithelial infiltrates resistant to topical steroids after adenoviral keratoconjunctivitis. 2014 Cornea pmid:25188789
Ricciardelli I et al. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. 2014 Blood pmid:25185261
Mujtaba MA et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. 2014 Am. J. Transplant. pmid:25179306
Rahman Z et al. Determination of tacrolimus crystalline fraction in the commercial immediate release amorphous solid dispersion products by a standardized X-ray powder diffraction method with chemometrics. 2014 Int J Pharm pmid:25173870
Chatterjea A et al. Suppression of the immune system as a critical step for bone formation from allogeneic osteoprogenitors implanted in rats. 2014 J. Cell. Mol. Med. pmid:24237965
Takeuchi T et al. Tacrolimus-induced left ventricular apical hypertrophy in a patient with post-allogeneic hematopoietic stem cell transplantation. 2014 Int. J. Cardiol. pmid:25131917
Huang H et al. Effect and mechanism of tacrolimus on melanogenesis on A375 human melanoma cells. 2014 Chin. Med. J. pmid:25131236
Kornblit B et al. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. 2014 Haematologica pmid:25085357
Sethna CB and Gipson DS Treatment of FSGS in Children. 2014 Adv Chronic Kidney Dis pmid:24602468
Guy S et al. Successful treatment of acute severe graft-versus-host-disease in a pancreas-after-kidney transplant recipient: case report. 2014 Transplant. Proc. pmid:25179161
Bercaw-Pratt JL et al. Clinical recommendation: pediatric lichen sclerosus. 2014 J Pediatr Adolesc Gynecol pmid:24602304
Yuan C et al. A simple and robust LC-MS/MS method for measuring sirolimus and everolimus in whole blood. 2014 Bioanalysis pmid:25077621
Kaieda S et al. Successful treatment of rectal ulcers in a patient with systemic lupus erythematosus using corticosteroids and tacrolimus. 2014 Mod Rheumatol pmid:24593214
Kraus TS et al. Angioimmunoblastic T cell lymphoma: an unusual presentation of posttransplant lymphoproliferative disorder in a pediatric patient. 2014 Acta Haematol. pmid:24157860
Bica L et al. Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation. 2014 PLoS ONE pmid:24587210
Little JA et al. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. 2014 J. Rheumatol. pmid:24085549
Hostettler KE et al. Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation. 2014 Eur. Respir. J. pmid:23645405
Beermann KJ et al. Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone. 2014 Clin Transplant pmid:24754564
Denfield SW Oxidative and other stresses following pediatric heart transplantation. 2014 Pediatr Transplant pmid:25250969
Izumi Y et al. Safety of tacrolimus treatment during pregnancy and lactation in systemic lupus erythematosus: a report of two patients. 2014 Tohoku J. Exp. Med. pmid:25175032
Boschetti G et al. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. 2014 Dig Liver Dis pmid:25023007
Okamoto T et al. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion associated with febrile urinary tract infection. 2014 Eur. J. Pediatr. pmid:24221606
Personett HA et al. Impact of molecular adsorbent recirculating system therapy on tacrolimus elimination: a case report. 2014 Transplant. Proc. pmid:25017243
Steinebrunner N et al. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation. 2014 Transpl Infect Dis pmid:24666466
Anderson JS et al. Statistical allosteric coupling to the active site indole ring flip equilibria in the FK506-binding domain. 2014 Biophys. Chem. pmid:25016286
Tapirdamaz Ö et al. Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. 2014 Pharmacogenet. Genomics pmid:25014506
Matsuda Y et al. Once-daily oral administration of cyclosporine in a lung transplant patient with a history of renal toxicity of calcineurin inhibitors. 2014 Interact Cardiovasc Thorac Surg pmid:24659549
Lunde I et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. 2014 Eur. J. Clin. Pharmacol. pmid:24658827
Kluk J et al. Follicular mucinosis treated with topical 0.1% tacrolimus ointment. 2014 Clin. Exp. Dermatol. pmid:24252117
Matsumoto K et al. [Perioperative agranulocytosis induced by immunosuppressants in a renal graft recipient : a case report]. 2014 Hinyokika Kiyo pmid:25001642
Friedrich RB et al. Nanoencapsulation of tacrolimus in lipid-core nanocapsules showed similar immunosuppressive activity after oral and intraperitoneal administrations. 2014 J Biomed Nanotechnol pmid:25016659
Rostaing L et al. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. 2014 Ann. Transplant. pmid:25017487
Jannot M et al. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. 2014 Ann. Transplant. pmid:24999809
Wannhoff A et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. 2014 Transplantation pmid:25022236
Sureshkumar KK and Chopra B In search of an optimal induction agent in kidney transplantation. 2014 Transplantation pmid:24978038
Kim SH et al. Expression, purification and characterization of soluble recombinant peptidyl-prolyl cis/trans isomerase from Vibrio anguillarum. 2014 Protein Expr. Purif. pmid:24931498
Enderby CY et al. Tacrolimus dosage requirements in lung transplant recipients receiving antifungal prophylaxis with voriconazole followed by itraconazole: a preliminary prospective study. 2014 Clin Transplant pmid:24931421
Webster P et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. 2014 Lupus pmid:24928830
Carbajo-Lozoya J et al. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. 2014 Virus Res. pmid:24566223
Tran D et al. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature. 2014 Exp Clin Transplant pmid:24844288
Feng S et al. A rapidly reversible chemical dimerizer system to study lipid signaling in living cells. 2014 Angew. Chem. Int. Ed. Engl. pmid:24841150
Rotter D et al. Calcineurin and its regulator, RCAN1, confer time-of-day changes in susceptibility of the heart to ischemia/reperfusion. 2014 J. Mol. Cell. Cardiol. pmid:24838101
Ren Y et al. Tolerogenic dendritic cells modified by tacrolimus suppress CD4(+) T-cell proliferation and inhibit collagen-induced arthritis in mice. 2014 Int. Immunopharmacol. pmid:24836681
Li H et al. A promising approach of overcoming the intrinsic resistance of Candida krusei to fluconazole (FLC)--combining tacrolimus with FLC. 2014 FEMS Yeast Res. pmid:24830342
Wang YB et al. In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization. 2014 AAPS PharmSciTech pmid:24824172
Welzl K et al. Effect of different immunosuppressive drugs on immune cells from young and old healthy persons. 2014 Gerontology pmid:24434865
Yang LM et al. Experimental research on end-to-side anastomosis of peripheral nerves and effect of FK506 on end-to-side anastomosis. 2014 Bratisl Lek Listy pmid:25573729
Uemoto S et al. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24767340
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
Muduma G et al. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. 2014 J Med Econ pmid:24754700
Shihab FS et al. Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study. 2014 Clin Transplant pmid:24754603
Parashos SA et al. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. 2014 JAMA Neurol pmid:24711047
Taube D et al. Generic tacrolimus in solid organ transplantation. 2014 Clin Transplant pmid:24750309
Bloch J et al. Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients. 2014 Pharmacogenomics pmid:25521359
Gillard P et al. Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. 2014 Transplantation pmid:24770614
Nacif LS et al. An analysis of tacrolimus-related complications in the first 30 days after liver transplantation. 2014 Clinics (Sao Paulo) pmid:25518032
Cvetkovic TP et al. Gender differences in oxidative and nitrosative stress parameters in kidney transplant patients on tacrolimus-based immunosuppression. 2014 Int Urol Nephrol pmid:24101297
Chen Y et al. Comparison of long-term impact of immunosuppressants at therapeutic doses on hepatic function and histological changes in unilateral nephrectomized rats. 2014 Exp. Toxicol. Pathol. pmid:25081300
Elens L et al. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. 2014 Br J Clin Pharmacol pmid:24118098
Xie M et al. Brucellosis infection in an adult liver transplant recipient. 2014 Transpl Infect Dis pmid:24666385
Takazono T et al. Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report. 2014 BMC Infect. Dis. pmid:24576098